Latest news with #SerumInstituteofIndia
The Hindu
5 hours ago
- Health
- The Hindu
‘Conquer HPV' conclave begins
The 'Conquer HPV (Human papillomavirus) & Cancer Conclave 2025' was launched here on Saturday (May 31) as part of a nationwide public health initiative led by the Serum Institute of India (SII). India continues to face a significant burden of HPV-related diseases, particularly cervical cancer, which remains the second most common cancer among women in the country, said a release issued here. According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and over 77,000 related deaths annually. Apart from this, up to 90% of anal cancers & 63% of penile cancers are associated with HPV, it said. Speakers at a discussion held here on the public health implications of HPV said that early awareness and timely prevention were essential, with peak HPV infection occurring between the ages of 15 to 25, according to the release.
Hindustan Times
20 hours ago
- Health
- Hindustan Times
Men should also take HPV vaccine: Experts
Health experts said that males can spread human papillomavirus (HPV) to their female partners and are also at risk. While HPV is often associated with cervical cancer in women, it also causes several serious diseases in men, including penile cancer, anal cancer, and oropharyngeal cancer as well as genital warts. Panel of medical specialists took part in discussion on public health implications of HPV at the 'Conquer HPV & Cancer Conclave 2025' organised by the Serum Institute of India (SII). They advised routine screening tests to detect HPV-related disease early in girls. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. 'Through these conclaves held across the country, we aim to increase understanding of HPV and its link to cervical and other cancers,' said Parag Deshmukh, executive director, SII. Experts said vaccinating boys and girls at young age can help strengthen their immune systems before they are exposed to the HPV virus.
India Today
3 days ago
- Health
- India Today
Covid-19 cases rising: What is the status of India's vaccine stockpile?
As cases of Covid-19 show signs of resurgence, sources in the government have assured that India has enough vaccine stockpile for its citizens and support exports to other countries, if 1,010 active cases were recorded as of May 26, with new infections reported from Noida, Lucknow, Karnataka, Mumbai, Arunachal Pradesh, and Varanasi, raising concerns of another potential sources told India Today that there is an ample stockpile of Covid-19 vaccines ready for deployment. "We are fully prepared for any situation. We have enough stockpile to meet the requirements of our citizens. Moreover, if needed, we can even supply vaccines to other countries," the sources Most of India, nearly 1 billion people, have received at least one dose of Covishield or manufactured under licence from AstraZeneca by the Serum Institute of India (SII), ceased its production in December 2021 due to reduced Covaxin, India's first indigenous Covid-19 vaccine, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology, stopped production in early the halt in manufacturing, officials say that vaccine availability is not a concern. India's existing vaccines were not designed to target these newer subvariants. () While doctors attribute this surge to the unpredictable seasonal pattern of respiratory illnesses, global health authorities point to diminishing protection from previous infections and vaccinations that could be playing a role in regional India, the dominant strains currently in circulation are LF.7, XFG, and JN.1, alongside the new Omicron sub-lineage variants have overlapping symptoms that closely mimic the common flu: cough, runny nose, sore throat, low-grade fever, headaches, body aches, and, in some cases, gastrointestinal the seasonal behaviour of SARS-CoV-2 now mirrors that of other respiratory viruses, driven by periodic mutations, there's a main difference: India's existing vaccines were not designed to target these newer this, health experts maintain that those who have been previously infected or vaccinated, especially within the past year, are still expected to retain some degree of protection against severe illness, even if they contract a mutated version of the virus. Most of India, nearly 1 billion people, have received at least one dose of Covishield or Covaxin. () Whether India will require updated Covid-19 vaccines remains under evaluation. However, emerging research offers reassurance.A recent study by the University of Arizona Health Sciences, published in Nature Immunology, found that prior vaccination continues to provide strong immune protection, even against newer variants like Delta and it may reduce the body's ability to generate variant-specific antibodies, vaccinated individuals still mounted a more robust immune response compared to those who were never InMust Watch
News18
24-05-2025
- Entertainment
- News18
Natasha Poonawalla Just Turned Herself Into A Gift At Cannes
Last Updated: For her appearance at the amfAR gala at Cannes, Natasha Poonawalla dressed head to toe in Balenciaga. After delivering some striking looks at the Met Gala in New York earlier this month, philanthropist and businesswoman Natasha Poonawalla is currently in Cannes. Recently, the Executive Director of the Serum Institute of India and the chairperson of the Villoo Poonawalla Foundation attended the amfAR gala that was held at the Cannes Film Festival. For her appearance at the event, she opted for a head-turning gold look by Balenciaga. Taking to her Instagram, Natasha Poonawalla shared a series of pictures of herself in her gold ensemble. The pictures showed her striking some stunning poses on the terrace with the French Riviera in the background. In other pictures, she was seen lying down on a white couch. She also included pictures from the amfAR dinner. Sharing these pictures, she wrote, 'Wake up and Show up!" Take a closer look at Natasha's OOTD here. View this post on Instagram A post shared by Natasha Poonawalla (@ For her appearance at the amfAR gala, Natasha opted for a statement strapless gold dress from Balenciaga. The strapless number was originally a part of the brand's Resort 2025 look. The sleeveless dress mimicked gold foil gift packaging, and it was a statement in itself. The gown came with a fitted bodice that was balanced by the voluminous details that mimicked a crushed gold packaging. It also came with a train that grazed the floor. Natasha paired this dress with Balenciaga's 9 AM clutch that looked like an on-the-go coffee cup. The philanthropist slipped into a pair of black pointed toe heels by Balenciaga. For the glam, Natasha went with a flawlessly matte base. She defined her eyes with a soft brown smokey eye look. She added a winged eyeliner and mascara to accentuate her eyes further. She contoured her face to highlight her sharp features. She added a muted brown shade on her lips and completed her look by leaving her hair open. First Published: May 24, 2025, 09:42 IST
&w=3840&q=100)
First Post
20-05-2025
- Entertainment
- First Post
Cannes 2025: Karan Johar says his father sold Kabhi Khushi Kabhie Gham for only $5000 at the festival 'Aishwarya and Shah Rukh were here and…'
He added, 'I thought it was very less and I asked my father about it. He told me, 'Look, we have to make a start somewhere.' He wasn't there to see the cultural movement we created with Bollywood films.' read more Karan Johar has arrived at the Cannes 2025 too and has dropped some unheard revelations at the festival about his film Kabhi Khushi Kabhie Gham and also Aishwarya Rai and Shah Rukh Khan. The filmmaker revealed, 'I have a lot of emotional memories of Cannes. I remember it was 2002 when I came here with my father. He struck a deal here and we sold the European rights of Kabhi Khushi Kabhie Gham for five thousand dollars.' STORY CONTINUES BELOW THIS AD He added, 'I thought it was very less and I asked my father about it. He told me, 'Look, we have to make a start somewhere.' He wasn't there to see the cultural movement we created with Bollywood films.' Karan also said, 'Aishwarya and Shah Rukh were on the red carpet. Aishwarya is literally like the queen of Cannes. Every time we are here, Ash creates a huge amount of media energy and excitement.' In 2024, Karan Johar sold 50 per cent stake of his production house - Dharma Productions to Adar Poonawalla, Chief Executive Officer of Serum Institute of India for Rs 1000 crore. The filmmaker recently spoke about this decision and shared that they needed funds for the growth of the company. 'I didn't want to do collaborative projects so that all the profitability stays with Dharma Productions. Our biggest hits at that time all had partners because we couldn't finance those films on our own ability, because we were new,' Karan told Raj Shamani on his YouTube channel. Talking about his late father Yash Johar's legacy, he shared, 'Those who say nepotism, they don't know my history. I inherited goodwill from my father but not money. Before Kuch Kuch Hota Hai, we had 5 flops in a row.' Karan recalled that it was his film Kuch Kuch Hota Hai that resurrected Dharma Productions. 'Kuch Kuch Hota Hai's release in 1998 marked the beginning of Dharma Productions as a strong company. What I had was my father's goodwill and his tremendous belief. He had tremendous goodwill, he was loved a lot but he didn't see success.' STORY CONTINUES BELOW THIS AD
